SAMHSA extends methadone take-home flexibilities initiated during pandemic
The Substance Abuse and Mental Health Services Administration yesterday extended certain methadone take-home flexibilities for opioid treatment programs until one year after the end of the COVID-19 public health emergency, and said it is considering ways to make the flexibilities permanent.
SAMHSA in 2020 allowed states to request a blanket exception to allow stable patients in an opioid treatment program to receive 28 days of take-home doses of their OUD medication, and other eligible patients to receive up to 14 days of take-home medication, which the agency said has enhanced and encouraged use of treatment services.
Related News Articles
Headline
In this conversation, a team from the University Medical Center New Orleans — LSU School of Medicine’s Benjamin Springgate, M.D., professor of …
Headline
Heidi Bray, DNP, nurse practitioner and hospitalist at Providence St. Peter Hospital, explores how hospitals can improve opioid use disorder treatment through…
Headline
The AHA will host a webinar June 16 at 1 p.m. ET that will share insights from its Bridge to Care Toolkit, designed to help hospitals and health systems…
Headline
The Drug Enforcement Administration today released a final rule implementing provisions from the Restoring Hope for Mental Health and Well-Being Act of 2022,…
Headline
The AHA has won two Telly Awards for its three-part video series, Voices of Leadership: Breaking Mental Health Stigma. The Telly Awards, a global…
Headline
In this conversation, three leaders from CommonSpirit Health explore how the organization is confronting stigma about substance use head-on through education,…